We are live on ! Find out more
Citadel Advisors

Citadel Advisors Portfolio holdings

AUM $875B
1-Year Est. Return 40.91%
 

Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.

This Fund
S&P 500
This Quarter Est. Return
+3.75%
1 Year Est. Return
+40.91%
3 Year Est. Return
+115.85%
5 Year Est. Return
+132.1%
10 Year Est. Return
+518.81%
AUM
$218B
AUM Growth
+$17B
Cap. Flow
+$6.68B
Cap. Flow %
3.06%
Top 10 Hldgs %
22.81%
Holding
10,425
New
1,217
Increased
3,775
Reduced
3,854
Closed
1,335

Top Buys

Rank Stock Value
1
NFLX icon
Netflix
NFLX
+$400M
2
C icon
Citigroup
C
+$395M
3
CELG
Celgene Corp
CELG
+$360M
4
AMZN icon
Amazon
AMZN
+$347M
5
RTX icon
RTX Corp
RTX
+$344M

Sector Composition

Rank Sector Weight
1 Technology 5.61%
2 Financials 4.93%
3 Healthcare 4%
4 Consumer Discretionary 3.82%
5 Industrials 3.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MRKR icon
8226
CALL
Marker Therapeutics
MRKR
$19M
$131K ﹤0.01%
+1,650
New +$98K
NOA
8227
CALL
North American Construction
NOA
$375M
$131K ﹤0.01%
12,100
+400
+3% +$4.65K
UEC icon
8228
CALL
Uranium Energy
UEC
$5.55B
$131K ﹤0.01%
95,900
+21,000
+28% +$28.9K
RVNC
8229
CALL
DELISTED
Revance Therapeutics, Inc.
RVNC
$131K ﹤0.01%
10,100
-16,000
-61% -$202K
TRUE
8230
CALL
DELISTED
TrueCar
TRUE
$130K ﹤0.01%
23,800
+9,200
+63% +$56.4K
FSM icon
8231
CALL
Fortuna Silver Mines
FSM
$3.16B
$129K ﹤0.01%
45,100
+13,300
+42% +$38.4K
LPL icon
8232
CALL
LG Display
LPL
$3.5B
$129K ﹤0.01%
16,700
+6,000
+56% +$47.7K
PRTA icon
8233
PUT
Prothena Corp
PRTA
$455M
$129K ﹤0.01%
12,200
-1,300
-10% -$13.4K
WTI icon
8234
CALL
W&T Offshore
WTI
$554M
$129K ﹤0.01%
26,100
-600
-2% -$3.23K
VJET
8235
DELISTED
VOXELJET AG American Depositary Shares (each representing one Ordinary Share)
VJET
$129K ﹤0.01%
14,046
+8,690
+162% +$84K
JNCE
8236
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$129K ﹤0.01%
26,004
-52,709
-67% -$280K
ATTO
8237
DELISTED
Atento S.A.
ATTO
$128K ﹤0.01%
10,258
-34,738
-77% -$545K
WAIR
8238
DELISTED
WESCO Aircraft Holdings Inc.
WAIR
$128K ﹤0.01%
11,561
-18,253
-61% -$175K
CCRN
8239
DELISTED
Cross Country Healthcare
CCRN
$127K ﹤0.01%
13,493
-58,237
-81% -$448K
SNDA icon
8240
Sonida Senior Living
SNDA
$1.88B
$127K ﹤0.01%
1,685
ZIXI
8241
CALL
DELISTED
Zix Corporation
ZIXI
$127K ﹤0.01%
+14,000
New +$122K
CMO
8242
PUT
DELISTED
Capstead Mortgage Corp.
CMO
$127K ﹤0.01%
+15,200
New +$128K
AOD
8243
abrdn Total Dynamic Dividend Fund
AOD
$1.14B
$126K ﹤0.01%
+15,092
New +$125K
IDT icon
8244
IDT Corp
IDT
$1.66B
$126K ﹤0.01%
13,355
-2,142
-14% -$15.8K
LCTX icon
8245
Lineage Cell Therapeutics
LCTX
$271M
$126K ﹤0.01%
114,117
+19,970
+21% +$23K
NGD
8246
CALL
DELISTED
New Gold Inc
NGD
$126K ﹤0.01%
130,600
-47,400
-27% -$37.7K
SRNE
8247
PUT
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$126K ﹤0.01%
47,100
+9,600
+26% +$34.5K
QTNT
8248
PUT
DELISTED
Quotient Limited Ordinary Shares
QTNT
$126K ﹤0.01%
+338
New +$121K
MRCC
8249
DELISTED
Monroe Capital Corp
MRCC
$125K ﹤0.01%
+10,811
New +$129K
OPCH icon
8250
Option Care Health
OPCH
$3.59B
$125K ﹤0.01%
+11,972
New +$98K

Similar funds

Citadel Advisors's Q2 2019 Portfolio in Review

As of Q2 2019, Citadel Advisors held 10,425 positions worth $218B, up 8.5% from $201B the previous quarter. Its ten largest holdings account for 23% of the portfolio.

Citadel Advisors deployed $6.68B of net new capital in Q2 2019, opening 1,217 new positions and adding to 3,775 existing holdings. Its largest new stake was Uber: 7,077,910 shares worth $328M.

By sector, the portfolio is most concentrated in Technology at 5.6% of assets, down from 6% a quarter earlier, followed by Financials and Healthcare.

On the sell side, the largest reduction was Eli Lilly, an estimated $397M trimmed.

  • Citadel Advisors's largest Q2 2019 buy was Uber: 7,077,910 shares worth $328M.
  • Citadel Advisors added most to Netflix in Q2 2019, an estimated $400M increase.
  • Citadel Advisors's biggest Q2 2019 reduction was Eli Lilly, cutting an estimated $397M.
  • Citadel Advisors fully exited Ultimate Software Group Inc in Q2 2019, selling an estimated $349M.
  • Citadel Advisors's ten largest holdings make up 23% of its $218B portfolio in Q2 2019.
  • Citadel Advisors opened 1,217 new positions and closed 1,335 in Q2 2019.
  • Citadel Advisors's portfolio value rose 8.5% quarter-over-quarter to $218B.

Based on Citadel Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.